Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy